Jounce Therapeutics, Inc. (NASDAQ:JNCE) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Wednesday.
According to Zacks, “Jounce Therapeutics, Inc. is a clinical-stage immunotherapy company. It engaged in developing therapies which enable the immune system to attack tumors. The Company’s lead product candidate, JTX-2011, is a clinical-stage monoclonal antibody that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of certain T cells found in a range of solid tumors. It also developing JTX-4014 for use in future combinations with JTX-2011, as well as for use in combination with other future product candidates. Jounce Therapeutics, Inc. is based in Cambridge, United States. “
JNCE has been the subject of a number of other reports. Robert W. Baird reaffirmed an “outperform” rating and set a $30.00 price target on shares of Jounce Therapeutics in a research note on Monday, September 18th. J P Morgan Chase & Co set a $28.00 price target on Jounce Therapeutics and gave the stock a “buy” rating in a research note on Monday. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. The stock has a consensus rating of “Buy” and an average price target of $23.67.
Shares of Jounce Therapeutics (NASDAQ JNCE) opened at $14.13 on Wednesday. Jounce Therapeutics has a one year low of $11.05 and a one year high of $29.29.
Jounce Therapeutics (NASDAQ:JNCE) last posted its quarterly earnings results on Monday, November 13th. The company reported ($0.13) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.25) by $0.12. The firm had revenue of $18.10 million for the quarter, compared to analysts’ expectations of $20.00 million. The firm’s revenue was up 7.1% on a year-over-year basis. equities analysts anticipate that Jounce Therapeutics will post -0.73 EPS for the current year.
COPYRIGHT VIOLATION WARNING: This news story was originally published by Week Herald and is owned by of Week Herald. If you are accessing this news story on another publication, it was illegally stolen and reposted in violation of United States and international copyright & trademark law. The correct version of this news story can be viewed at https://weekherald.com/2017/11/15/jounce-therapeutics-inc-jnce-upgraded-at-zacks-investment-research.html.
Hedge funds and other institutional investors have recently modified their holdings of the company. Fosun International Ltd acquired a new position in shares of Jounce Therapeutics during the 2nd quarter valued at about $1,456,000. Conning Inc. increased its holdings in shares of Jounce Therapeutics by 36.0% during the 3rd quarter. Conning Inc. now owns 125,960 shares of the company’s stock valued at $1,962,000 after acquiring an additional 33,350 shares during the last quarter. Geode Capital Management LLC acquired a new position in shares of Jounce Therapeutics during the 1st quarter valued at about $1,573,000. Prudential Financial Inc. acquired a new position in shares of Jounce Therapeutics during the 2nd quarter valued at about $958,000. Finally, Spark Investment Management LLC increased its holdings in shares of Jounce Therapeutics by 104.7% during the 2nd quarter. Spark Investment Management LLC now owns 125,300 shares of the company’s stock valued at $1,757,000 after acquiring an additional 64,100 shares during the last quarter. 44.47% of the stock is currently owned by institutional investors and hedge funds.
Jounce Therapeutics Company Profile
Jounce Therapeutics, Inc is a clinical stage immunotherapy company. The Company is engaged in transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long lasting benefits to patients. Through the use of its Translational Science Platform, Jounce first focuses on specific cell types within tumors to prioritize targets, and then identifies related biomarkers designed to match the right therapy to the right patient.
Receive News & Ratings for Jounce Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jounce Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.